Hepatoprotective Benefits of SGLT-2 Inhibitors and GLP-1 Analogs

Dear Editor Metabolic dysfunction-associated steatotic liver disease (MASLD) and its advanced form and metabolic dysfunction-associated steatohepatitis (MASH) are growing health concerns linked to metabolic syndrome and type 2 diabetes mellitus (T2DM). Addressing these conditions effectively requires innovative treatments that target their complex nature.[1] Recent studies have shown that sodium-glucose cotransporter-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) analogs (), which are primarily used for controlling blood sugar in T2DM, also have significant liver-protective properties. These drugs could provide dual benefits in managing both metabolic and liver diseases, especially in individuals with T2DM and obesity.[2] SGLT-2 inhibitors: Medications, such as empagliflozin, dapagliflozin, and canagliflozin, have been found to lower liver fat and reduce liver inflammation. They achieve these effects by promoting weight loss, improving insulin sensitivity, and decreasing oxidative stress and inflammation. Research indicates that SGLT-2 inhibitors can lower liver enzymes (alanine transaminase and aspartate transaminase) and improve liver steatosis, positioning them as promising treatments for MASLD and MASH. Importantly, the weight reduction properties of SGLT-2 inhibitors contribute significantly to these benefits, as excess weight is a critical factor in the development of liver disease.[3] GLP-1 analogs: Drugs, such as liraglutide and semaglutide, protect the liver through various mechanisms. They support weight loss, enhance insulin sensitivity, and possess anti-inflammatory and anti-fibrotic properties. Clinical trials have shown that GLP-1 analogs can significantly reduce liver fat and improve liver histology. Notably, the LEAN trial demonstrated that liraglutide led to the histological resolution of nonalcoholic steatohepatitis in many patients. The weight loss induced by GLP-1 analogs is a major contributor to their effectiveness in treating liver conditions, as reducing body weight alleviates the metabolic burden on the liver.[4] Considering that T2DM and obesity are major risk factors for developing MASLD, these medications are particularly beneficial for patients with these conditions. Starting SGLT-2 inhibitors and GLP-1 analogs early in the course of T2DM may even prevent the development of MASLD and MASH, providing a proactive strategy for managing liver health. The combined benefits of these drugs on blood sugar control and liver health highlight their potential as key treatments for patients with T2DM and liver disease. Integrating SGLT-2 inhibitors and GLP-1 analogs into treatment plans for MASLD and MASH could slow the progression of liver disease and improve patient outcomes. Moreover, using these medications together could enhance their effects, as their complementary mechanisms might offer even greater protection for the liver. However, long-term studies are needed to confirm these benefits and determine the best use of these drugs in different patient groups. In summary, SGLT-2 inhibitors and GLP-1 analogs show great promise for managing MASLD and MASH in patients with T2DM and obesity. Their protective effects on the liver, alongside their ability to control blood sugar and reduce weight, could significantly improve treatment strategies for metabolic liver diseases. As we learn more about these medications, they are likely to become essential components of a comprehensive approach to treating the complexities of metabolic-associated liver diseases. Author contributions R.D. has contributed to data collection and manuscript preparation. S.A.R. has contributed to concept, scientific content, manuscript preparation, editing, and proofreading. We confirm that the manuscript has not been published and is not under consideration for publication in any other Journal. We confirm all authors approved the manuscript and its submission to the journal, and the authors have not published or submitted any related papers from the same study. Financial support and sponsorship Nil. Conflicts of interest There are no conflicts of interest.